We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Danish biotechnology company Genmab and US-based Seattle Genetics are set to co-develop tisotumab vedotin for the treatment of patients with solid tumours.